ADVA
6.5.2021 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that its FSP 3000 open line system (OLS) played a key role in a demo showcasing a real-time public safety application. In the METRO-HAUL field trial, AI-based thermal-imaging and pan-tilt-zoom video cameras were used to secure a surveillance area. Advanced video analytics and active camera control require the transport of high-bandwidth video and latency-critical control traffic to a remote control center. Using the ADVA FSP 3000 OLS with flexible micro-ROADMs as well as QuadFlex™ transponders, the demo featured a programmable metro network with edge nodes for time-critical computing. Conducted at Fraunhofer HHI’s test beds in Berlin as part of the 5G Infrastructure Public Private Partnership (5G PPP) initiative’s METRO-HAUL project, the trial involved ADVA and several research center and university partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210506005044/en/
“This METRO-HAUL demo reveals how modern metro networks with edge compute and storage functionality can support intelligent video surveillance systems to provide unprecedented power and efficiency. It also highlights how important network slicing will be in enabling the agile resource allocation needed to support high-bandwidth, ultra-low-latency applications such as automated object detection and tracking,” said Achim Autenrieth, director, advanced technology, ADVA. “Built on our FSP 3000 OLS with flexible micro-ROADMs and SDN control, this showcase highlights just how much operators can now achieve by deploying disaggregated 5G infrastructure with edge computing and network slicing capabilities. It illustrates that next-generation metro networks are ready to support a new breed of high-bandwidth, low-latency applications and take safety surveillance technology to the next stage.”
In the METRO-HAUL field trial, application-aware network slicing was used for prioritized transport of critical real-time video streams. Object tracking was performed by a video management and analytics service running locally as a virtual network function, and instantiated ad-hoc on an edge-compute-enabled metro node. The demo showed a high-definition video stream automatically tracing any object crossing the perimeter of the surveillance zone. The stream was then distributed to a central location for real-time analysis and remote incident control. Managed by ADVA’s Ensemble Controller with its proven SDN domain controller, the test network enabled rapid provisioning of high-bandwidth resources and offered end-to-end latency awareness. Flexible connectivity was provided by coherent transponders and an innovative ROADM-based OLS architecture optimized for metro network demands. The demo was selected as one of the Top 10 5G PPP Infrastructure Trials and Pilots.
“Alongside partners like ADVA, we’ve been working to rapidly develop transport network slicing and open the door to a world of new applications. Enabling multi-access edge computing right where it’s needed will be key to many emerging use cases. This METRO-HAUL field trial harnessing ADVA’s open transport technology shows how it’s now possible to create flexible end-to-end architectures that interface with both 5G access and multi-Tbit elastic core networks,” said Andrew Lord, senior manager, optical research, BT. “Right now, digitalization and 5G are transforming nearly every industry, and the impact on public safety technology will be hugely significant. As ADVA’s showcase proves, tomorrow’s networks will take speed, low latency, reliability and agility to the next level, enabling mission-critical security services to process, store and analyze more data and deliver more value than ever before.”
The results from the demo will be presented at the OFC 2021 technical conference on Friday, June 11 at 11 a.m. (PDT), Session ID - F4H.2: https://adva.li/ofc21-latency-aware-demo .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005044/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom